Article in Cancer research communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 2 institutions in 1 country.
Kiyoshi Saeki *Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-1214-3215
Wanglong Qiu *Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-2878-1251
Richard A FriedmanHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-5136-2998
Samuel PanHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-2860-0855
Jordan LuHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-3380-1125
Shu IchimiyaHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-8184-615X
Iok In Christine ChioHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-3635-2679
Carrie J ShawberDeparments of Obstetrics and Gynecology and Surgery, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-2654-3559
Jan KitajewskiDepartment of Physiology and Biophysics, University of Illinois Cancer Center, University of Illinois Chicago, Chicago, Illinois.ORCID 0000-0003-4660-593X
Jianhua HuHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-3306-6722
Gloria H SuHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-5158-6019
Columbia University Irving Medical Center · USUniversity of Illinois Chicago · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Notch in Angiogenesis and Vascular BiologyR01HL112626 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Jan K. Kitajewski · 2012 to 2026
$6.3M
The Development And Progression Of IPMN To PDA In The Context Of Inactivated Activin SignalingR01CA217207 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SU, GLORIA HUEI-TING · 2017 to 2021
$2.4M
Studying the role of eIF4A in Pancreatic CancerR01CA267870 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Christine Iok In Chio · 2022 to 2026
$2.3M
NRF2-dependent redox signaling in pancreatic cancerR01CA240654 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CHIO, CHRISTINE IOK IN · 2020 to 2024
$1.8M
Repurposing Bazedoxifene for chemoprevention in pre-invasive pancreatic cancer IPMNR21CA259715 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CHIO, CHRISTINE IOK IN · 2022 to 2023
Expression of the Notch family of receptors is often upregulated in pancreatic ductal adenocarcinoma (PDAC). In this study, we focused on Notch4, which had not been investigated in PDAC. We generated KC ( Significance: We demonstrated that global inactivation of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.